SCHEMBL6773596

SCHEMBL6773596

CCOC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)c1ccc(Cl)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 1/20 0.51
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CTSS P25774 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 1/20 0.46
KLKB1 P03952 1/20 0.46
EPHX2 P34913 1/20 0.46
PPARG P37231 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
PTGS2 P35354 1/20 0.46
LNPEP Q9UIQ6 1/20 0.45
NOD2 Q9HC29 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773591 0.81 GPR139 (0.53) GPR139KDM4ELMNASMN1; SMN2CTSS
SCHEMBL8019647 0.81 KLK5 (0.45) GPR139TP53CTSSRAB9A
SCHEMBL11025321 0.80 RAB9A (0.54) TP53LMNASMN1; SMN2KMT2AHPGD
SCHEMBL6778759 0.79 TP53 (0.48) GPR139TP53CA1CA2LMNA
SCHEMBL7825718 0.78 TP53 (0.47) GPR139TP53CA1CA2KMT2A
SCHEMBL16005297 0.77 ATM (0.62) LMNAKMT2AGAARAB9A
SCHEMBL6776476 0.77 NOS2 (0.51) GPR139KDM4ELMNAKMT2A
SCHEMBL6773783 0.77 NAMPT (0.52) TP53CA1CA2LMNAHPGD
SCHEMBL6778050 0.76 GPR139 (0.39) GPR139KDM4ETP53HPGDEPHX2
SCHEMBL11025325 0.76 HPGD (0.50) GPR139TP53LMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed